Animace načítání

Stránka se připravuje...

Přihlásit se Registrovat se
28 489 právních předpisů

Další údaje zde

Technická podpora

Poskytujeme technickou podporu zdarma

Zavolejte nám

+420 777 717 492

Plné znění - 32020R1182

  1. Úvodní strana
  2. Právní předpisy EU
  3. Plné znění - 32020R1182

Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

Chci získat výhodný přístup

XXXXXXXX KOMISE V XXXXXXXXX PRAVOMOCI (EU) 2020/1182

xx xxx 19. xxxxxx 2020,

xxxxxx se xxx účely přizpůsobení xxxxxxxxxxx a xxxxxxxxx xxxxxxx mění xxxx 3 xxxxxxx XX xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Rady (XX) x. 1272/2008 x xxxxxxxxxxx, označování x xxxxxx látek a xxxxx

(Xxxx x významem xxx XXX)

XXXXXXXX KOMISE,

s xxxxxxx xx Xxxxxxx x xxxxxxxxx Xxxxxxxx xxxx,

x xxxxxxx xx xxxxxxxx Evropského parlamentu x Xxxx (ES) x. 1272/2008 ze xxx 16. prosince 2008 o klasifikaci, xxxxxxxxxx x xxxxxx xxxxx x xxxxx, x změně a xxxxxxx xxxxxxx 67/548/XXX x 1999/45/XX x x změně nařízení (XX) č. 1907/2006&xxxx;(1), x xxxxxxx xx xx. 37 xxxx. 5 uvedeného xxxxxxxx,

xxxxxxxx x xxxxx xxxxxxx:

(1)

Xxxxxxx 3 x xxxxx 3 xxxxxxx XX xxxxxxxx (XX) x. 1272/2008 xxxxxxxx seznam xxxxxxxxxxxxxxx xxxxxxxxxxx a xxxxxxxx xxxxxxxxxxxx xxxxx xx základě xxxxxxxx xxxxxxxxxxx x xxxxxxx 2 xx 5 xxxxxxx X uvedeného xxxxxxxx.

(2)

Xxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxx („xxxxxxxx“) xxxx x souladu x článkem 37 xxxxxxxx (XX) x. 1272/2008 předloženy xxxxxx xx xxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxx látek x xxxxxxxxxxx xxxx zrušení xxxxxxxxxxxxxxx xxxxxxxxxxx a xxxxxxxx xxxxxxxxx xxxxxx xxxxx. Na xxxxxxx xxxxxxxxxx&xxxx;(2) k xxxxx xxxxxxx, xxxxx xxxxx Xxxxx xxx xxxxxxxxxx xxxxx („XXX“) xxxxxxxx, xxxxx i připomínek xxxxxxxxxxxx stran, xx xxxxxx zavést, aktualizovat xx zrušit harmonizované xxxxxxxxxxx a xxxxxxxx xxxxxxxxx xxxxx. Uvedená xxxxxxxxxx výboru XXX xxxx:

—

xxxxxxxxxx xx xxx 8. června 2018 xxxxxxx xxxxxxxx xxxxxxx... %[X ≤ 70 %],

—

xxxxxxxxxx xx dne 9. xxxxxx 2018 xxxxxxx xxxxxx x xxxxxxx xxxxxxx (x xxxxxxx < 3 μx,xxxxx &xx; 5 μx x xxxxxx xxxxx ≥ 3:1),

—

xxxxxxxxxx xx dne 8. xxxxxx 2018 ohledně xxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxx(xxxxx)xxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxxx, 6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxx-xxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxxxxx xxxx,

—

xxxxxxxxxx ze dne 30. xxxxxxxxx 2018 xxxxxxx bis (X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxxxxxx-X,X’)-xxxx, xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxxx, [Xx-XXX],

—

xxxxxxxxxx xx xxx 14. září 2018 ohledně xxxxxxxxxx-xxxxxxxxx, [1] xxxxxxxx, xxxxxxx-, xxx(xxxx xxxxxxx) derivátů [2],

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx dibenzo[def,p]chrysenu, xxxxxxx[x,x]xxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxx (XXX), (1XX,2XX,5XX;1XX,2XX,5XX)-2-(4-xxxxxxxxxxx)-5-xxxxxxxxx-1-(1X-1,2,4-xxxxxxx-1-xxxxxxxx)xxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 8. xxxxxx 2018 ohledně xxx(2-(2-xxxxxxxxxxxxx)xxxxx)xxxxxx, tetraglymu,

—

stanovisko ze xxx 8. xxxxxx 2018 xxxxxxx paklobutrazolu (XXX), (2XX,3XX)-1-(4-xxxxxxxxxxx)-4,4-xxxxxxxx-2-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-3-xxx,

—

xxxxxxxxxx xx xxx 8. června 2018 xxxxxxx 2,2-xxx(xxxxxxxxxx)xxxxxx-1,3-xxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxx, (2X)-3,7-xxxxxxxxxxxx-2,6-xxxx-1-xxx,

—

xxxxxxxxxx xx xxx 28. xxxxx 2019 ohledně 2-(4-xxxx-xxxxxxxxxxx)xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 ohledně XXXX-xxxxxxxxxx (XXX), X-xxxxx (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxxx, X-xxxxx 4-xxxxx-x-xxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 9. xxxxxx 2018 ohledně xxxxxxxxxx-xxxxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx 4-{[(6-xxxxxxxxxxxxx-3-xx)xxxxxx](2,2-xxxxxxxxxxxxx)xxxxx}xxxxx-2(5X)-xxx, xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxx-xxxxxxx (XXX), methyl 4- [(4,5-xxxxxxx-3-xxxxxxx-4-xxxxxx-5-xxx-1X-1,2,4-xxxxxxx-1-xx)xxxxxxxxxxxxxxxxx]-5-xxxxxxxxxxxxx-3-xxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. března 2018 xxxxxxx L-(+)-mléčné xxxxxxxx, (2X)-2-xxxxxxxxxxxxxxxx kyseliny,

—

stanovisko xx dne 9. xxxxxx 2018 xxxxxxx 2-xxxxxxxxxxxx-xxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx glyoxylové xxxxxxxx …%,

—

xxxxxxxxxx ze dne 14. září 2018 xxxxxxx xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx, [formaldehyd xxxxxxxx z xxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx],

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx (xxxxx-XXX-xxxxx)xxxxxxxxxxx draselného, xxxxxxxxxx(xxxxxxx)xxxxxx-1-xxxxx, xxxxxxxx xxxx, [X-XXX],

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxxx-xxxxxxxxxxx, N-ethyl-N,N-dimethylhexadekan-1-aminium-ethyl-sulfátu, xxxxxxxxxxx-xxxxx-xxxxxxx [XXX],

—

xxxxxxxxxx xx xxx 9. března 2018 xxxxxxx (2XX)-2-[4-(4-xxxxxxxxxxx)-2(xxxxxxxxxxxxxxx)xxxxx]-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-2-xxx, xxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxx (XXX), 1-(4-{4-[5-(2,6-xxxxxxxxxxxx)-4,5-xxxxxxx-1,2-xxxxxx-3-xx]-1,3-xxxxxxx-2-xx}xxxxxxxxx-1-xx)-2-[5-xxxxxx-3-(xxxxxxxxxxxxxxx)-1X-xxxxxxx-1-xx]xxxxxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 ohledně xxxxxxxxx-xxxxx, (X-4)-xxx[1-(xxxxxxx-xxxxx-X)xxxxxxx-2(1X)-xxxxxxx-xxxxx-X]xxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně 3-xxxxx-4-(xxxxxxxxxxx)-1-[3-xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xxx, xxxxxxxxxxxxxxx (ISO),

—

stanovisko xx xxx 30. listopadu 2018 ohledně 4,5-xxxxxxx-2-xxxxx-2X-xxxxxxxxxx-3-xxx, [XXXXX],

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx 2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xxx, [XXXX],

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně 3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxxx, fluxapyroxadu,

—

stanovisko xx xxx 8. xxxxxx 2018 xxxxxxx X-(xxxxxxxxxxxxx)xxxxxxxxxx, xxxxxxxxxxxxxxxxxx, [XXX],

—

xxxxxxxxxx xx xxx 15. xxxxx 2018 xxxxxxx 5-xxxxx-1,3-xxxxxxxx-X-[2-(4-xxxxxxxxxxxx-2-xx)xxxxx]-1X-xxxxxxx-4-xxxxxxxxxxx, 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxxx, xxxxxxxxxx,

—

xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 xxxxxxx iprovalikarbu (XXX), xxxxxxxxx [(2X)-3-xxxxxx-1-{[1-(4-xxxxxxxxxxx)xxxxx]xxxxx}-1-xxxxxxxx-2-xx]xxxxxxxxx,

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 ohledně xxxxxxxxxxx (XXX), N-allyl-4,5-dimethyl-2(trimethylsilyl)thiofen-3-karboxamidu,

—

stanovisko xx dne 9. xxxxxx 2018 xxxxxxx xxxxxxx, výtažku [olej xxxxxxxx za studena xx xxxxx rostliny Xxxxxxxxxxx indica xxx xxxxxxxx, extrahovaný xxxxxxxxxxxxxx xxxxxx uhličitým],

—

stanovisko xx xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxx xxxxxxx …%[C> 70 %],

—

xxxxxxxxxx x 9. xxxxxx 2018 ohledně xxxxxxxxxxxxxxxxxxxxxxxxxxxx, [D4],

—

stanovisko ze xxx 30. xxxxxxxxx 2018 xxxxxxx pirimifos-methylu (XXX), O-[2-(diethylamin)-6-methylpyrimidin-4-yl]-O,O-dimethyl-fosforthioátu,

—

stanovisko ze 30. listopadu 2018 xxxxxxx fosfinu,

—

stanovisko xx xxx 14. xxxx 2018 ohledně xxxxxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx 2-xxxxxxxxxx-10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxx-xxxxxxxxx, [XXXX],

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx olova,

—

stanovisko xx xxx 14. xxxx 2018 xxxxxxx 2-xxxxxxxxxxxxxx, ethylenglykol-monobutyl-etheru,

—

stanovisko ze xxx 30. xxxxxxxxx 2018 xxxxxxx x-xxx(2,3-xxxxxxxxxxxx)xxxxxxx, xxxxxxxxxx-xxxxxxxxxx-xxxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxx-xxxxxxx (XXX), xxxxxx 2-[N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-N-methylkarbamoylsulfamoyl]benzoátu,

—

stanovisko xx xxx 8. xxxxxx 2018 ohledně azoxystrobinu (XXX), methyl (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx (XXX), (XX)-2-xxxxxx-2,3-xxxxxxx-3,3-xxxxxxxxxxxxxxxxxx-5-xx-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně 2,4-xxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 14. září 2018 xxxxxxx xxxxxxxxxx (XXX), 2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 xxxxxxx okthilinonu (XXX), 2-xxxxx-2X-xxxxxxxxxx-3-xxx, [XXX],

—

xxxxxxxxxx ze xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxx (XXX), 3-xxxxxxx-5-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně xxxxxxxxxxxx (XXX), trans-5-(4-chlorfenyl)-N-cyklohexyl-4-methyl-2-oxo-3-thiazolidin-karboxamidu,

—

stanovisko xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxx (XXX), (E)-4,5-dihydro-6-methyl-4-(3-pyridylmethylen-amino)-1,2,4-triazin-3(2H)-onu,

—

stanovisko xx xxx 9. xxxxxx 2018 ohledně xxxxxxxxxxxx (XXX), xxxxxxx xxxxx: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxxx, [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthematu,

—

stanovisko xx xxx 14. xxxx 2018 butanon-oximu, xxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx bis(α,α-dimethylbenzyl)-peroxidu,

—

stanovisko xx xxx 9. xxxxxx 2018 xxxxxxx rozvětveného xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxxx hexyl 2-(1-(xxxxxxxxxxxxxxxxxxxxxxxx) xxxxxxxxx)xxxxxxxx, hexyl 2-[4-(xxxxxxxxxxx)-2-xxxxxxxxxxxxxx]xxxxxxxx.

(3)

Xxxxx xxx x látku xxxxx (číslo XXX 7439–92–1 a xxxxxxxx xxxxx 082–013–00–1 (xxxxx x xxxxxx; [xxxxxx xxxxxx &xx; 1 xx];) x 082–014–00–7 (xxxxxxxx xxxxx; [průměr xxxxxx ≥ 1 xx];)), XXX xx xxxx xxxxxxxxxx ze xxx 30. listopadu 2018 xxxxxx použít xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx xx xxxxxxxxx x xxxxxxxxx formu. Avšak xxxxxxxx x xxxxx xxxxxxxxx xxxxxxxxxxx celistvé xxxxx, tvárné struktuře xxxxx, ke xxxxxxxxxx xxxxxxx xxxxxx xxxxxx x xxxxxxxx x xxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxxxx x xxxxxxxxxx forem jiných xxxx x existujících xxxxxxxxx v xxxxxxx XX musí XXX xxxxxxx xxxxx posouzení xxxx, zda má xxx na xxxxxxxxx x práškovou xxxxx xxxxx xxxxxxx xxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx. Xxxxx xxxx byly předloženy xxxx xxxxxxx xxxxxxxx, x nichž xxxxxxx, xx xxxxxxxxxxxxxxx klasifikace xxx xxxxxxxxx xxxxx, xxx xx xxxxxxxxxx xxxxxxxxxx výboru XXX, xxxxxx xxx xxxxxx. Xxxxxxxxxxxxxxx klasifikace xxx xxxxxxxxx xxxxx xxxxx xxxxxx xxxxxxxx xx xxxxxxx XX xxxxxxxx (XX) x. 1272/2008, xxxxx XXX xxxxxx xxx xxxxxxx předložit xxxxxxxxxx xxxxxxxxxx.

(4)

Xxxxx xxx x xxxxx 2-xxxxxxxxxxxxx, xxxxxxxxxxxxx-xxxxxxxxx-xxxxx, (xxxxx XXX 111-76-2), xxx xxxxx xxxxxxxxxxxxx „xxxxxx xxxxxxxx (xxxxxxxxx)“ byly xxxxxxxxxx xxxx xxxxxxx poznatky, xx xxxxxxx vyplývá, xx klasifikace xxx xxxx třídu xxxxxxxxxxxxx xxxxxxxxxxxx ve stanovisku xxxxxx RAC, xxx xx xxxxxxx xx xxxxxxxx údajích, nemusí xxx vhodná. Tato xxxxx xxxxxxxxxxxxx by xxxxx neměla xxx x xxxxxxx XX xxxxxxxx (XX) x. 1272/2008 xxxxxxx, xxxxx XXX xxxxxx xxx xxxxxxx xxxxxxxxx k xxxxx xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxxx; xxxxxxx xxxxxxx xxxxx xxxxxxxxxxxxx, x xxxxxxx xxxxxxxxx xxxxxxxxxx výboru XXX, xx xxxxxxxx být xxxx.

(5)

Xxxxxxxx (XX) x. 1272/2008 by proto xxxx být xxxxxxxxxxxxx xxxxxxxx změněno.

(6)

Dodržování xxxxxx xxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx by nemělo xxx, x xxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx, xxxxxxxxxx xxxxx, xxxxxxx xxxxxxxxxx xxxxxxxxx určitou xxxx xx to, xxx xxxxxxxxxxxx označování x xxxxxx látek x xxxxx xxxxx xxxx xxxxxxxxxxx xxxxxxxxxxxx x xxxxxxx stávající xxxxxx. Xxxx xxxx xx rovněž xxxxxxxx x xxxx, xxx xxxxxxxxxx měli xxxxxxxx xxxx xxxxxxxx opatření xxxxx k zajištění xxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxx xxxxxxxxx, xxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxx xxxxx xxxxxx xxxxxxxx. Xxxx xxxxxxxxx xxxxx zahrnovat xxxxxxxxx xxxxxxxxx x xx. 22 xxxx. 1 xxxx. x) xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Rady (XX) x. 1907/2006&xxxx;(3) nebo xxxxxxxxx xxxxxxxxx x xxxxxx 50 xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 528/2012&xxxx;(4).

(7)

Xxxxxxxxxxx by však xxxx xxx xxxxxxxx, xxx xxxxx xxxx xxxxxxxxxx xxxxxxxx xx xxxxxxxxxxx, označování x xxxxxx xxxxxxxxxx dobrovolně xxxxx xxxx xxxxxxxxxxxxx xxxxxx nařízení. Xx xx v souladu x přístupem xxxxx xx. 61 xxxx. 2 xxxxxxxx (ES) x. 1272/2008,

XXXXXXX XXXX XXXXXXXX:

Xxxxxx 1

Xxxxx xxxxxxxx (XX) x. 1272/2008

Xxxxxxx 3 x xxxxx 3 přílohy XX xxxxxxxx (XX) x. 1272/2008 xx xxxx x xxxxxxx x xxxxxxxx xxxxxx xxxxxxxx.

Článek 2

Vstup v xxxxxxxx a xxxxxxxxxxxx

Xxxx xxxxxxxx vstupuje x xxxxxxxx xxxxxxxx xxxx xx vyhlášení x Xxxxxxx věstníku Evropské xxxx.

Xxxxxxx xx xxx xxx 1. března 2022.

Xxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx xxxxxx xxxxx být xxxxx x směsi klasifikovány, xxxxxxxxxx x baleny x souladu s xxxxxxxxx (ES) č. 1272/2008 xx xxxxx xxxxxx xxxxxxxx xxxxx xxxxx xxxx 1. xxxxxx 2022.

Toto xxxxxxxx xx xxxxxxx x xxxxx xxxxxxx x xxxxx xxxxxxxxxx xx xxxxx xxxxxxxxx státech.

V Xxxxxxx xxx 19. xxxxxx 2020.

Xx Xxxxxx

Xxxxxx XXX XXX XXXXX

xxxxxxxxxxx

(1)&xxxx;&xxxx;xxxxXx. věst. X 353, 31.12.2008, x. 1.

(2)&xxxx;&xxxx;Xxxxxxxxxx xxxx xxxxxxxx xx xxxx xxxxxxxxxxx xxxxxxx: https://echa.europa.eu/registry-of-clh-intentions-until-outcome/-/dislist/name/-/ecNumber/-/casNumber/-/dte_receiptFrom/-/dte_receiptTo/-/prc_public_status/Opinion+Adopted/dte_withdrawnFrom/-/dte_withdrawnTo/-/sbm_expected_submissionFrom/-/sbm_expected_submissionTo/-/dte_finalise_deadlineFrom/-/dte_finalise_deadlineTo/-/haz_addional_hazard/-/lec_submitter/-/dte_assessmentFrom/-/dte_assessmentTo/-/prc_regulatory_programme/-/

(3)  Nařízení Xxxxxxxxxx xxxxxxxxxx a Xxxx (XX) x. 1907/2006 xx dne 18. prosince 2006

o xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx x xxxxxxxxx xxxxxxxxxx xxxxx, x xxxxxxx Xxxxxxxx xxxxxxxx pro xxxxxxxx xxxxx, o xxxxx směrnice 1999/45/XX x o xxxxxxx xxxxxxxx Xxxx (XXX) x. 793/93, xxxxxxxx Xxxxxx (XX) x. 1488/94, xxxxxxxx Rady 76/769/XXX x směrnic Xxxxxx 91/155/XXX, 93/67/EHS, 93/105/XX a 2000/21/XX (Xx. věst. X 396, 30.12.2006, x. 1).

(4)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 528/2012 xx xxx 22. xxxxxx 2012

x xxxxxxxx xxxxxxxxxx xxxxxxxxx xx trh x xxxxxx xxxxxxxxx

(Xx. xxxx. X 167, 27.6.2012, x. 1).

XXXXXXX

X xxxxxxx VI xxxxxxxx (XX) x. 1272/2008 xx xxxxxxx 3 v xxxxx 3 mění xxxxx:

1)

Xxxxxxxx xx xxxx položky:

Indexové xxxxx

Xxxxxxxx xxxxx

Xxxxx XX

Xxxxx XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx xxxxxxx. xxxxxx, xxxxxxxxxxxxx xxxxxxx x XXX

Xxxxxxxx

Xxxx xxxx x xxxxxxxxx xxxxxxxxxxxxx

Xxxx xxxxxxxxxxxx xxx o xxxxxxxxxxxxx

Xxxx xxxxxxxxxxx xxxxxxx x xxxxxxxxxx slov

Kódy xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

Xxxx xxxxx. xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

„007-030-00-3

xxxxxxxx xxxxxxx …% [X ≤ 70 %]

231-714-2

7697-37-2.

Ox. Xxx. 3

Xxxxx Tox. 3

Xxxx Xxxx. 1 A

H272

H331

H314

GHS03

GHS06

GHS05

Dgr

H272

H331

H314

EUH071

Ox. Xxx. 3; X272: X ≥ 65 %

xxxxxxxxx: ATE = 2,65 xx/x (xxxx)

Xxxx Xxxx. 1 X; X314: X ≥ 20 %

Xxxx Xxxx. 1X; X314: 5 % ≤ X &xx; 20 %

B“

„014-048-00-5

vlákna x karbidu xxxxxxx (x průměru < 3 μx, xxxxx &xx; 5 μx x x xxxxxxx xxxxx ≥ 3:1)

206-991-8

409-21-2

308076-74-6

Carc. 1X

X350x

XXX08

Xxx

X350x“

„014-049-00-0

xxxxxxxxxxxxxxxxxxxx; xxxxxxxxxx(xxxxx)xxxxx

220-449-8

2768-02-7

Xxxx Xxxx. 1X

X317

XXX07

Xxx

X317“

„014-050-00-6

xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxx;

6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxx

213-934-0

1067-53-4

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„016-098-00-3

xxxxxxxx-xxxxxxxx

210-871-0

624-92-0

Xxxx. Liq. 2

Xxxxx Xxx. 3

Xxxxx Xxx. 3

XXXX SE 3

XXXX XX 1

Eye Xxxxx. 2

Skin Xxxx. 1

Xxxxxxx Acute 1

Aquatic Xxxxxxx 1

H225

H331

H301

H336

H370 (horní xxxxxxx xxxxx, xxxxxxxxx)

X319

X317

X400

X410

XXX02

XXX06

XXX08

XXX09

Xxx

X225

X331

X301

X336

X370 (xxxxx dýchací xxxxx, xxxxxxxxx)

X319

X317

X410

xxxxxxxxx: ATE = 5 xx/x (xxxx)

xxxxxx: XXX = 190 xx/xx XX

X = 1

X = 10“

„029-024-00-X

granulovaná xxx;

[xxxxx xxxxxx: od 0,9 mm x xx 6,0 xx; xxxxx částic: xx 0,494 xx 0,949 xx]

231-159-6

7440-50-8

Xxxxxxx Xxxxxxx 2

X411

XXX09

X411“

„029-025-00-5

xxx(X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxxxxxx-X,X’)xxx;

xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxx;

[Xx-XXX]

239-703-4

312600-89-8

15627-09-5

Xxxx. Xxx. 1

Xxxxx Xxx. 4

XXXX XX 2

Xxx Xxx. 1

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

H228

H302

H373 (xxxxx)

X318

X400

X410

XXX02

XXX07

XXX08

XXX05

XXX09

Xxx

X228

X302

X373 (xxxxx)

X318

X410

xxxxxx: XXX = 360 xx/xx XX

X = 1

X = 1“

„050-031-00-9

dioktylcín-dilaurát; [1]

xxxxxxx, xxxxxxx-, xxx(xxxx xxxxxxx) xxxxxxxx [2]

222-883-3 [1] 293-901-5 [2]

3648-18-8 [1] 91648-39-4 [2]

Repr. 1B

STOT XX 1

X360X

X372 (xxxxxxxx xxxxxx)

XXX08

Xxx

X360X

X372 (xxxxxxxx xxxxxx)“

„601-092-00-0

xxxxxxx[xxx,x]xxxxxxx;

xxxxxxx[x,x]xxxxx

205-886-4

191-30-0

Xxxx. 1X

Xxxx. 2

X350

X341

XXX08

Xxx

X350

X341

Xxxx. 1X; X350: X ≥ 0,001 %“

„603-237-00-3

ipkonazol (XXX);

(1XX,2XX,5XX;1XX,2XX,5XX)-2-(4-xxxxxxxxxxx)-5-xxxxxxxxx-1-(1X-1,2,4-xxxxxxx-1-xxxxxxxx)xxxxxxxxxxxxx

–

125225-28-7

115850-69-6

115937-89-8

Xxxx. 1X

Xxxxx Tox. 4

XXXX XX 2

Aquatic Xxxxxxx 1

X360X

X302

X373 (oči, xxxx, xxxxx)

X410

XXX08

XXX07

XXX09

Xxx

X360X

X302

X373 (oči, kůže, xxxxx)

X410

xxxxxx: XXX = 500 xx/xx TH

M = 100“

„603-238-00-9

xxx(2-(2-xxxxxxxxxxxxx)xxxxx)-xxxxx; xxxxxxxxx

205-594-7

143-24-8

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„603-239-00-4

xxxxxxxxxxxxx (XXX);

(2XX,3XX)-1-(4-xxxxxxxxxx)-4,4-xxxxxxxx-2-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-3-xx

–

76738-62-0

Xxxx. 2

Xxxxx Xxx. 4

Xxxxx Tox. 4

Xxx Xxxxx. 2

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X361x

X332

X302

X319

X400

X410

XXX08

XXX07

XXX09

Xxx

X361x

X332

X302

X319

X410

xxxxxxxxx: ATE = 3,13 mg/l (prach xxxx xxxx)

xxxxxx: ATE = 490 xx/xx XX

X = 10

M = 10“

„603-240-00-X

2,2-xxx(xxxxxxxxxx)xxxxxx-1,3-xxxx

221-967-7

3296-90-0

Xxxx. 1X

Xxxx. 1X

X350

X340

XXX08

Xxx

X350

X340“

„603-241-00-5

xxxxxxxx;

(2X)-3,7-xxxxxxxxxxxx-2,6-xxxx-1-xx

203-377-1

106-24-1

Xxxx Xxxx. 1

X317

XXX07

Xxx

X317“

„605-041-00-3

2-(4-xxxx-xxxxxxxxxxx)xxxxxxxx

201-289-8

80-54-6

Xxxx. 1X

X360Xx

XXX08

Xxx

X360Xx“

„607-738-00-8

XXXX-xxxxxxxxx (ISO);

S-ethyl (4-chlor-2-methylfenoxy)ethanethioát; X-xxxxx 4-chlor-o-tolyloxythioacetát

246-831-4

25319-90-8

Acute Xxx. 4

XXXX XX. 2

Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1

H302

H373 (játra)

H400

H410

GHS07

GHS08

GHS09

Wng

H302

H373 (xxxxx)

X410

xxxxxx: XXX = 450 xx/xx XX

X = 10

X = 10“

„607-740-00-9

xxxxxxxxxx-xxxxxx

248-523-5

27554-26-3

Xxxx. 1B

H360FD

GHS08

Dgr

H360FD“

„607-741-00-4

4-{[(6-chlorpyridin-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on; xxxxxxxxxxxxxx

–

951659-40-8

Xxxxx Xxx. 4

STOT XX 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X302

X373 (xxxxxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X373 (xxxxxxxxx)

X410

xxxxxx: XXX = 500 mg/kg TH

M = 10

X = 10“

„607-742-00-X

xxxxxxxxxxxxx-xxxxxx (XXX);

xxxxxx-4-[(4,5-xxxxxxx-3-xxxxxxx-4-xxxxxx-5-xxx-1X-1,2,4-xxxxxxx-1-xx)xxxxxxxxxxxxxxxxx]-5-xxxxxxxxxxxxx-3-xxxxxxxxxx

–

317815-83-1

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X400

X410

XXX09

Xxx

X410

X = 1000

X = 1000“

„607-743-00-5

X-(+)-xxxxxx xxxxxxxx;

(2 X)-2-xxxxxxxxxxxxxxxx xxxxxxxx

201-196-2

79-33-4

Xxxx Xxxx. 1C

Eye Xxx. 1

X314

X318

XXX05

Xxx

X314

XXX071“

„607-744-00-0

2-xxxxxxxxxxxxxxxxxxx

221-499-3

3121-61-7

Xxxx. Xxx. 3

Xxxx. 2

Repr. 1X

Xxxxx Xxx. 3

Xxxxx Tox. 4

Xxxx Xxxx. 1X

Xxx Xxx. 1

Xxxx Xxxx. 1

X226

X341

X360XX

X331

X302

X314

X318

X317

XXX02

XXX05

XXX06

XXX08

Xxx

X226

X341

X360XX

X331

X302

X314

X317

XXX071

xxxxxxxxx: ATE = 2,7 xx/x (xxxx)

xxxxxx: XXX = 404 xx/xx TH“

„607-745-00-6

glyoxylová kyselina …%

206-058-5

298-12-4

Xxx Xxx. 1

Xxxx Xxxx. 1X

X318

X317

XXX05

XXX07

Xxx

X318

X317

X“

„607-746-00-1

xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxx;

[xxxxxxxxxxx xxxxxxxx x xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx]

274-357-8

70161-44-3

Xxxx. 1X

Xxxx. 2

Xxxxx Tox. 4

Xxxxx Xxx. 4

XXXX SE 3

Xxxx Xxxxx. 2

Eye Xxxxx. 2

Skin Xxxx. 1

X350

X341

X332

X302

X335

X315

X319

X317

XXX08

XXX07

Xxx

X350

X341

X332

X302

X335

X315

X319

X317

xxxxxxxxx: XXX = 3 xx/x (prach xxxx xxxx)

xxxxxx: ATE = 1&xxxx;100 mg/kg XX

8

9“

„611-181-00-6

(xxxxx-XXX-xxxxx)xxxxxxxxxx draselný;

cyklohexylhydroxydiazen-1-oxid, draselná xxx;

[X-XXX]

–

66603-10-9

Xxxx. Sol. 1

Xxxxx Xxx. 3

XXXX XX 2

Xxxx Xxxxx. 2

Xxx Xxx. 1

Xxxxxxx Xxxxxxx 2

X228

X301

X373 (xxxxx)

X315

X318

X411

XXX02

XXX06

XXX08

XXX05

XXX09

Xxx

X228

X301

X373 (xxxxx)

X315

X318

X411

xxxxxx: XXX = 136 xx/xx TH“

„612-294-00-3

mecetroniumetilsulfát;

N-ethyl-N,N-dimethylhexadekan-1-aminium-ethyl-sulfát;

mecetronium-ethyl-sulfát;

[MES]

221-106-5

3006-10-8

Skin Corr. 1

Xxx Xxx. 1

Aquatic Xxxxx 1

Xxxxxxx Chronic 1

X314

X318

X400

X410

XXX05

XXX09

Xxx

X314

X410

XXX071

X = 100

M = 1&xxxx;000 “

„613-331-00-6

(2XX)-2-[4-(4-xxxxxxxxxxx)-2-(xxxxxxxxxxxxxx)xxxxx]-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-2-xx;

xxxxxxxxxxxxxxxxxx

–

1417782-03-6

Xxxx Xxxx. 1

Xxxxxxx Acute 1

Xxxxxxx Chronic 1

X317

X400

X410

XXX07

XXX09

Xxx

X317

X410

X = 1

X = 1“

„613-332-00-1

xxxxxxxxxxxxxxx (XXX);

1-(4-{4-[5-(2,6-xxxxxxxxxxxx)-4,5-xxxxxxx-1,2-xxxxxx-3-xx]-1,3-xxxxxxx-2-xx}xxxxxxxxx-1-xx)-2-[5-xxxxxx-3-(xxxxxxxxxxxxxx)-1X-xxxxxxx-1-xx]xxxxxxx

–

1003318-67-9

Xxxxxxx Xxxxxxx 1

X410

XXX09

Xxx

X410

X = 1“

„613-333-00-7

pyrithion-zinek; (X-4)-xxx[1-(xxxxxxx-.xxxxx.X)xxxxxxx-2(1X)-xxxxxxxx-.xxxxx.X]xxxxx

236-671-3

13463-41-7

Xxxx. 1X

Xxxxx Tox. 2

Xxxxx Xxx. 3

XXXX XX 1

Eye Xxx. 1

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

H360D

H330

H301

H372

H318

H400

H410

GHS08

GHS06

GHS05

GHS09

Dgr

H360D

H330

H301

H372

H318

H410

inhalační: XXX = 0,14 mg/l (xxxxx xxxx mlha)

orální: XXX = 221 xx/xx XX

X = 1&xxxx;000

X = 10“

„613-334-00-2

flurochloridon (XXX);

3-xxxxx-4-(xxxxxxxxxxx)-1-[3-(xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xx

262-661-3

61213-25-0

Xxxx. 1X

Xxxxx Xxx. 4

Xxxx Xxxx. 1

Aquatic Xxxxx 1

Aquatic Xxxxxxx 1

X360XX

X302

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X360XX

X302

X317

X410

xxxxxx: XXX = 500 xx/xx XX

X = 100

M = 100“

„613-335-00-8

4,5-xxxxxxx-2-xxxxx-2X-xxxxxxxxxx-3-xx; [XXXXX]

264-843-8

64359-81-5

Xxxxx Tox. 2

Xxxxx Xxx. 4

Skin Xxxx. 1

Xxx Xxx. 1

Xxxx Xxxx. 1 X

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X330

X302

X314

X318

X317

X400

X410

XXX06

XXX05

XXX09

Xxx

X330

X302

X314

X317

X410

XXX071

xxxxxxxxx: XXX = 0,16 xx/x (xxxxx xxxx xxxx)

xxxxxx: XXX = 567 xx/xx XX

Xxxx Irrit. 2; X315: 0,025 % ≤ X &xx; 5 %

Eye Xxxxx. 2; H319: 0,025 % ≤ X &xx; 3 %

Xxxx Xxxx. 1 X; X317: X ≥ 0,0015 %

M = 100

X = 100“

„613-336-00-3

2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xx;

[XXXX]

–

2527-66-4

Xxxxx Xxx. 4

Xxxxx Xxx. 3

Skin Corr. 1X

Xxx Xxx. 1

Xxxx Xxxx. 1 A

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 2

X312

X301

X314

X318

X317

X400

X411

XXX06

XXX05

XXX09

Xxx

X312

X301

X314

X317

X410

XXX071

xxxxxxxx: XXX = 1&xxxx;100 xx/xx TH

orální: XXX = 175 xx/xx TH

Skin Xxxx. 1 X; H317: X ≥ 0,0015 %

X = 1“

„616-228-00-4

3-(difluormethyl)-1-methyl-N-(3‘,4’,5’-trifluorbifenyl-2-yl)pyrazol-4-karboxamid;

fluxapyroxad

–

907204-31-3

Lact.

Aquatic Xxxxx 1

Xxxxxxx Chronic 1

X362

X400

X410

XXX09

Xxx

X362

X410

X = 1

M = 1“

„616-230-00-5

X-(xxxxxxxxxxxxx)xxxxxxxxx; methylolakrylamid; [XXX]

213-103-2

924-42-5

Xxxx. 1X

Xxxx. 1X

XXXX XX 1

H350

H340

H372 (periferní xxxxxxx xxxxxx)

XXX08

Xxx

X350

X340

X372 (xxxxxxxxx xxxxxxx xxxxxx)“

„616-231-00-0

5-xxxxx-1,3-xxxxxxxx-X-[2-(4-xxxxxxxxxxxx-2-xx)xxxxx]-1X-xxxxxxx-4-xxxxxxxxxx; 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxx;

xxxxxxxxx

–

494793-67-8

Xxxx. 2

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X351

X400

X410

XXX08

XXX09

Xxx

X351

X410

X = 1

X = 1“

„616-232-00-6

xxxxxxxxxxxx (XXX);

xxxxxxxxx [(2S)-3-methyl-1-{[1-(4-methylfenyl)ethyl]amino}-1-oxobutan-2-yl]karbamát

–

140923-17-7

Carc. 2

X351

XXX08

Xxx

X351“

„616-233-00-1

xxxxxxxxxx (XXX);

X-xxxxx-4,5-xxxxxxxx-2-(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxx

–

175217-20-6

XXXX XX 2

Xxxxxxx Xxxxxxx 2

X373

X411

XXX08

XXX09

Xxx

X373

X411“

„650-057-00-6

Xxxxxxx, výtažek [xxxx xxxxxxxx xx xxxxxxx xx xxxxx xxxxxxxx Azadirachta indica xxx skořápek, xxxxxxxxxxx xxxxxxxxxxxxxx xxxxxx uhličitým]

283-644-7

84696-25-3

Aquatic Xxxxxxx 3

X412

X412“

2)

xxxxxxx odpovídající xxxxxxxxx číslům 007-004-00-1; 014-018-00-1; 015-134-00-5; 015-181-00-1; 050-021-00-4; 050-027-00-7; 082-013-00-1; 603-014-00-0; 603-065-00-9; 605-019-00-3; 607-177-00-9; 607-256-00-8; 607-314-00-2; 609-041-00-4; 609-064-00-X; 613-112-00-5; 613-115-00-1; 613-125-00-6; 613-202-00-4; 613-259-00-5; 616–014–00–0 a 617–006–00-X xx xxxxxxxxx xxxxxx položkami:

Indexové xxxxx

Xxxxxxxx xxxxx

Xxxxx XX

Xxxxx XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx xxxxxxx. xxxxxx, xxxxxxxxxxxxx xxxxxxx x XXX

Xxxxxxxx

Xxxx xxxx x kategorií xxxxxxxxxxxxx

Xxxx xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

Xxxx xxxxxxxxxxx xxxxxxx x xxxxxxxxxx xxxx

Xxxx standardních xxx x xxxxxxxxxxxxx

Xxxx xxxxx. xxxxxxxxxxxx vět x xxxxxxxxxxxxx

„007-004-00-1

xxxxxxxx dusičná …% [X &xx; 70 %]

231-714-2

7697-37-2

Xx. Xxx. 2

Xxxxx Xxx. 1

Xxxx Xxxx. 1 X

X272

X330

X314

XXX03

XXX06

XXX05

Xxx

X272

X330

X314

XXX071

Xx. Liq. 2; H272: C ≥ 99 %

Xx. Xxx. 3; X272: 70 % ≤ X &xx; 99 %

X“

„014-018-00-1

xxxxxxxxxxxxxxxxxxxxxxxxxxx;

[X4]

209-136-7

556-67-2

Xxxx. 2

Aquatic Xxxxxxx 1

X361x ***

X410

XXX08

XXX09

Xxx

X361x ***

X410

X = 10“

„015-134-00-5

pirimifos-methyl (XXX);

X-[2-(xxxxxxxxxxx)-6-xxxxxxxxxxxxxxx-4-xx]-X,X-xxxxxxxx-xxxxxxxxxxxxx

249-528-5

29232-93-7

Xxxxx Xxx. 4

XXXX RE 1

Xxxxxxx Acute 1

Aquatic Xxxxxxx 1

X302

X372 (nervový xxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X372 (nervový xxxxxx)

X410

xxxxxx: XXX = 1&xxxx;414 xx/xx XX

X = 1&xxxx;000

X = 1&xxxx;000 “

„015-181-00-1

xxxxxx

232-260-8

7803-51-2

Xxxx. Gas 1

Xxxxx. Xxx

Xxxxx Tox. 1

Skin Xxxx. 1B

Aquatic Xxxxx 1

X220

X330

X314

X400

XXX02

XXX04

XXX06

XXX05

XXX09

Xxx

X220

X330

X314

X400

xxxxxxxxx:

XXX = 10 xxxX (plyny)

U“

„050-021-00-4

dichlordioktylstannan

222-583-2

3542-36-7

Repr. 1X

Xxxxx Xxx. 2

XXXX XX 1

Xxxxxxx Chronic 3

X360X

X330

X372 **

X412

XXX08

XXX06

Xxx

X360X

X330

X372 **

X412

Xxxx. 1X; X360 D: C ≥ 0,03 %

inhalační: XXX = 0.098 xx/X (xxxxx xxxx xxxx)“

„050-027-00-7

2-xxxxxxxxxx 10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxxxxxxxxxx; [XXXX]

239-622-4

15571-58-1

Xxxx. 1X

XXXX XX 1

Aquatic Xxxxx 1

Xxxxxxx Chronic 1

X360X

X372 (xxxxxxxx systém)

H400

H410

GHS08

GHS09

Dgr

H360D

H372 (xxxxxxxx xxxxxx)

X410“

„082-013-00-1

xxxxxxx prášek; [xxxxxx xxxxxx &xx; 1 xx]

231-100-4

7439-92-1

Xxxx. 1 X

Xxxx.

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X360XX

X362

X400

X410

XXX08

XXX09

Xxx

X360XX H362

H410

Repr. 1 A; X360X: X ≥ 0,03 %

X = 1

M = 10“

„603-014-00-0

2-xxxxxxxxxxx-1-xx;

xxxxxxxxxxxxxxxxxxxxxxxxxxxx

203-905-0

111-76-2

Xxxxx Xxx. 4*

Xxxxx Xxx. 4

Skin Xxxxx. 2

Eye Xxxxx. 2

X332

X302

X315

X319

XXX07

Xxx

X332

X302

X315

X319

xxxxxx: ATE = 1&xxxx;200 mg/kg TH“

„603-065-00-9

m-bis(2,3-epoxypropoxy)benzen;

resorcinoldiglycidylether

202-987-5

101-90-6

Carc. 1X

Xxxx. 2

Xxxxx Tox. 3

Xxxxx Xxx. 4

Xxxx Xxxxx. 2

Eye Irrit. 2

Xxxx Xxxx. 1

Xxxxxxx Xxxxxxx 3

H350

H341

H311

H302

H315

H319

H317

H412

GHS08

GHS06

Dgr

H350

H341

H311

H302

H315

H319

H317

H412

dermální: XXX = 300 xx/xx XX xxxxxx: XXX = 500 xx/xx XX“

„607-177-00-9

xxxxxxxxxx-xxxxxx (ISO);

methyl-2-[N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-N-methylkarbamoylsulfamoyl]benzoát

401-190-1

101200-48-0

STOT XX 2

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X373

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X373

X317

X410

X = 100

X = 100“

„607-256-00-8

xxxxxxxxxxxx (XXX);

xxxxxx (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxx

–

131860-33-8

Xxxxx Xxx. 3

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 1

X331

X400

X410

XXX06

XXX09

Xxx

X331

X410

xxxxxxxxx:

XXX = 0,7 xx/x (prach xxxx xxxx)

X = 10

X = 10“

„607-314-00-2

xxxxxxxxxxx (ISO);

(RS)-2-ethoxy-2,3-dihydro-3,3-dimethylbenzofuran-5-yl xxxxxxxxxxxxxx

247-525-3

26225-79-6

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X400

X410

XXX09

Xxx

X410

X = 1

X = 1“

„609-041-00-4

2,4-xxxxxxxxxxxx

200-087-7

51-28-5

Xxxxx Xxx. 3 *

Xxxxx Xxx. 3

Xxxxx Tox. 2

XXXX XX 1

Aquatic Xxxxx 1

H331

H311

H300

H372

H400

GHS06

GHS08

GHS09

Dgr

H331

H311

H300

H372

H400

dermální: ATE = 300 mg/kg XX orální: XXX = 30 mg/kg XX“

„609-064-00-X

xxxxxxxxx (ISO);

2-[4-(methylsulfonyl)-2-nitrobenzoyl]-1,3-cyklohexandion

–

104206-82-8

Repr. 2

XXXX XX 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X361x

X373 (xxx, xxxxxxx systém)

H400

H410

GHS08

GHS09

Wng

H361d

H373 (xxx, xxxxxxx xxxxxx)

X410

X = 10

X = 10“

„613-112-00-5

xxxxxxxxxx (ISO);

2-oktyl-2H-isothiazol-3-on; [OIT]

247-761-7

26530-20-1

Acute Xxx. 2

Xxxxx Xxx. 3

Xxxxx Xxx. 3

Xxxx Xxxx. 1

Xxx Dam. 1

Xxxx Sens. 1 X

Xxxxxxx Acute 1 Xxxxxxx Xxxxxxx 1

X330

X311

X301

X314

X318

X317

X400

X410

XXX06

XXX05

XXX09

Xxx

X330

X311

X301

X314

X317

X410

XXX071

xxxxxxxxx: XXX = 0,27 xx/x (xxxxx xxxx xxxx)

xxxxxxxx: XXX = 311 xx/xx XX xxxxxx: XXX = 125 xx/xx TH

Skin Xxxx. 1 A; X317: X ≥ 0,0015 %

X = 100

X = 100“

„613-115-00-1

xxxxxxxxx (XXX);

3-xxxxxxx-5-xxxxxxxxxxxxxx

233-000-6

10004-44-1

Xxxx. 2

Xxxxx Tox. 4

Xxx Xxx. 1

Skin Xxxx. 1

Xxxxxxx Chronic 2

X361x

X302

X318

X317

X411

XXX08

XXX07

XXX05

XXX09

Xxx

X361x

X302

X318

X317

X411

xxxxxx: XXX = 1&xxxx;600 xx/xx XX“

„613-125-00-6

xxxxxxxxxxx (XXX);

xxxxx-5-(4-xxxxxxxxxx)-X-xxxxxxxxxx-4-xxxxxx-2-xxx-3-xxxxxxxxxxx-xxxxxxxxxx

–

78587-05-0

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X400

X410

XXX09

Xxx

X410

X = 1

X = 1“

„613-202-00-4

xxxxxxxxxx (XXX);

(X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxxxxxxxx)-1,2,4-xxxxxxx-3(2X)-xx

–

123312-89-0

Xxxx. 2

Xxxx. 2

Xxxxxxx Xxxxxxx 1

X351

X361xx

X410

XXX08

XXX09

Xxx

X351

X361xx

X410

X = 1“

„613-259-00-5

xxxxxxxxxxx (ISO);

reakční xxxx: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxx; [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxxxx-xxxxxxxxxxxxx

428-790-6

72963-72-5

Xxxx. 2

Acute Xxx. 4

Acute Xxx. 4

XXXX SE 2

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X351

X332

X302

X371 (nervový xxxxxx; xxxxxx, inhalační)

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H332

H302

H371 (nervový xxxxxx; xxxxxx, inhalační)

H410

inhalační: XXX = 1,4 xx/x (xxxxx nebo xxxx)

xxxxxx: XXX = 550 xx/xx TH

M = 10

X = 10“

„616-014-00-0

xxxxx-xx-xxxx; xxxxxxxxxxxxxxxxxx, xxxxx(xxxxxx)xxxxxxxxx

202-496-6

96-29-7

Xxxx. 1X

Xxxxx Xxx. 4

Xxxxx Xxx. 3

XXXX SE 3

XXXX XX 1

XXXX XX 2

Xxxx Irrit. 2

Xxx Xxx. 1

Xxxx Xxxx. 1

H350

H312

H301

H336

H370 (horní xxxxxxx xxxxx)

X373 (xxxxxx xxxx)

X315

X318

X317

XXX08

XXX06

XXX05

Xxx

X350

X312

X301

X336

X370 (xxxxx xxxxxxx xxxxx)

X373 (krevní oběh)

H315

H318

H317

dermální: XXX = 1&xxxx;100 xx/xx XX xxxxxx: XXX = 100 xx/xx XX“

„617-006-00-X

xxx(α,α-xxxxxxxxxxxxxx)xxxxxxx

201-279-3

80-43-3

Xxx. Xxxxx. X

Xxxx. 1B

Skin Xxxxx. 2

Xxx Irrit. 2

Xxxxxxx Xxxxxxx 2

H242

H360D

H315

H319

H411

GHS02

GHS08

GHS07

GHS09

Dgr

H242

H360D

H315

H319

H411“

3)

položky xxxxxxxxxxxx xxxxxxxxx číslům 601-064-00-8 x 607-693-00-4 se xxxxxxx.